Human medicines European public assessment report (EPAR): Strimvelis, autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence, Date of authorisation: 26/05/2016, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Qtern, saxagliptin,dapagliflozin, Date of authorisation: 15/07/2016, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Xigduo, dapagliflozin,metformin, Date of authorisation: 16/01/2014, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Ebymect, dapagliflozin,metformin, Date of authorisation: 15/11/2015, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Cosentyx, secukinumab, Date of authorisation: 14/01/2015, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR): Leflunomide ratiopharm, leflunomide, Date of authorisation: 28/11/2010, Revision: 20, Status: Authorised

Agenda - Management Board meeting: 17-18 December 2025

Human medicines European public assessment report (EPAR): Mepact, mifamurtide, Date of authorisation: 06/03/2009, Revision: 22, Status: Authorised

Minutes of the PRAC meeting 27 - 30 October 2025

Human medicines European public assessment report (EPAR): Caelyx pegylated liposomal, doxorubicin, Date of authorisation: 20/06/1996, Revision: 39, Status: Authorised